TABLE 1.

Clinical characteristics of seven M. intracellulare patients who responded to BDQ and then relapsed

Patient	Age (yr)	Disease typea	Duration of prior treatment (mo)	Companion drugs while on BDQb	Resistance		AFB smear status			7H11 agar culture status
					Macrolide	Amikacin	Pretreatment	Lowest on BDQ	Relapse	Pretreatment	Lowest on BDQ	Relapse
1c	54	FN + C	96	EMB, RFB, STR	Yes	No	4+	Negative	3+	4+	Negative	4+
2c	60	NB	25	AZM, EMB, RFB, STR	No	No	4+	Negative	3+	4+	Negative	4+
3	68	FN + C	48	AMK, EMB, RFB	Yes	No	3+	Negative	2+	4+	Negative	2+
4	71	NB + C		AMK, AZM, EMB, STR	No	No	3+	Negative	2+	4+	Negative	3+
5c	58	NB	78	EMB, RFB, STR	Yes	Yes	4+	2+	4+	4+	3+	4+
6	66	NB + C	44	AMK, EMB, RFB	Yes	Yes	3+	Negative	2+	3+	+d	3+
7	64	FN + C	20	CLR, EMB, RFB, STR	No	No	3+	Negative	3+	4+	Negative	3+

^aFN, fibronodular; NB, nodular bronchiectasis; C, cavitary.

^bAMK, amikacin; AZM, azithromycin; CLR, clarithromycin; EMB, ethambutol; RFB, rifabutin; STR, streptomycin.

^cPreviously described by Philley et al. (15).

^dOnly 8 CFU were observed.